Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04612517
NCT04612517CompletedEarly Phase 1

A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of ZP7570 in Healthy Subjects

Zealand Pharma1 site in 1 country40 target enrollmentStarted: October 26, 2020Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Early Phase 1
Status
Completed
Enrollment
40
Locations
1
Primary Endpoint
Safety and Tolerability - Incidence of treatment emergent adverse events as assessed by type and severity
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a randomised, double-blind, placebo-controlled, multiple ascending dose trial in healthy subjects, randomised to ZP7570 or placebo within each cohort

Detailed Description

Forty subjects are planned to be studied in four cohorts in this multiple ascending dose trial. Ten subjects will be allocated to four dose levels. Intermediate dose levels may be applied. A sentinel dosing approach (sequential dosing) will be applied. The entire observation period comprises 51 days starting with a 96 hours in-house stay after the first dose injection, where discharge is planned for Day 5, followed by one outpatient visit. For the second and the third injection dose a 36 hours in-house stay is planned. After the fourth dose injection there is also a 96 hour in-house stay where discharge is planned for Day 26, followed by five outpatient visits and an End of Trial Visit on Day 51. A blinded evaluation of each cohort will be performed by a Trial Safety Group to determine whether the trial will progress to the next planned dose level based on the stopping rules specified in the protocol.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 55 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Signed and dated informed consent obtained before any trial-related activities. Trial-related activities are any procedures that would not have been done during normal management of the subject.
  • •Healthy male or female subject (only women not of childbearing potential) aged between 18 and 55 years, both inclusive.
  • •Body Mass Index (BMI) between 18.5 and 28.0 kg/m2, both inclusive
  • •A body weight of at least 60 kg.
  • •Heart rate after 5 minutes rest in supine position inside the range of 50-90 beats/min at screening

Exclusion Criteria

  • •Any history of a disorder which in the investigator's opinion might jeopardize subjects safety, evaluation of results or compliance with the protocol.
  • •History of gallbladder disease or cholecystectomy.
  • •History of pancreatitis
  • •History of major depressive disorder or a Patient Health Questionnaire (PHQ-9) > 9 completed at screening, or a history of other severe psychiatric disorders (e.g. schizophrenia or bipolar disorder).
  • •Any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to screening.
  • •Family history of multiple endocrinological neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC).
  • •Clinically significant abnormal standard 12-lead ECG after 5 min resting in supine position at screening, including a QTcF > 450 ms (males) or QTcF > 470 ms (females), PR ≥ 220 ms and QRS ≥ 110 ms.
  • •History of severe hypersensitivity to medicines or foods or history of severe medicinal/food induced anaphylactic reaction .
  • •Any clinically significant abnormal hematology, biochemistry, or urinalysis screening tests, as judged by the investigator.
  • •TSH values outside of normal reference ranges of safety laboratory
  • •Estimated glomerular filtration rate (eGFR) < 90 ml/min/1.73 m2, as defined by - Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
  • •Known or suspected hypersensitivity to IMP(s) or related products.
  • •Systolic blood pressure < 90 mmHg or >139 mmHg and/or diastolic blood pressure < 50 mmHg or > 89 mmHg (one repeat test will be acceptable in case of suspected white-coat hypertension).
  • •Symptoms of arterial hypotension
  • •Women of childbearing potential
  • •Men with non-pregnant partner(s) of childbearing potential not willing to use male contraception (condom) in addition to a highly effective contraceptive method until 28 days after dosing
  • •Men with pregnant partner not willing to use male contraception (condom) until 28 days after dosing, in order to avoid exposure of the embryo/fetus to seminal fluid.

Arms & Interventions

ZP7570

Experimental

Four ascending doses of ZP7570

Intervention: ZP7570 (Drug)

Placebo

Placebo Comparator

Corresponding volume of placebo

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Safety and Tolerability - Incidence of treatment emergent adverse events as assessed by type and severity

Time Frame: From time 0 to 51 days after first dosing (29 days after fourth dosing) ]

The incidence, type and severity of treatment emergent adverse events

Secondary Outcomes

  • Pharmacokinetics - Area under the plasma concentration-time curve - infinity(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacokinetics - Volume of distribution - Vz/f(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacodynamics - Plasma glucose concentration-time curves(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCplasma glucose,0-240min(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCfree fatty acids, 0-60min(From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCfree fatty acids, 0-240min(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacokinetics - Area under the plasma concentration-time curve - through(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacokinetics - Maximum plasma concentration - Cmax(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacokinetics - Time to maximum plasma concentration - Tmax(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacokinetics - Elimination rate constant - λz(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacokinetics - Half-life - t½(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacokinetics - Body clearance - CL/f(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacokinetics - Mean residence time - MRT(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacodynamics - Maximum acetaminophen concentration - Cmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose)
  • Pharmacodynamics - Time to maximum acetaminophen concentration - Tmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacokinetics - Area under the plasma concentration-time curve - last(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Pharmacodynamics - Acetaminophen concentration-time curves(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCacetaminohen,0-60min(From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCacetaminohen,0-240min(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Maximum plasma glucose concentration - Cmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the the forth dose)
  • Pharmacodynamics - Time to maximum plasma glucose concentration - Tmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Time to maximum insulin concentration - Tmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Time to maximum glucagon concentration - Tmax (optional)(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCplasma glucose,0-60min(From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Insulin concentration-time curves(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Maximum insulin concentration - Cmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCinsulin,0-60min(From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCinsulin, 0-240min(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Glucagon concentration-time curves (optional)(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Maximum glucagon concentration - Cmax (optional)(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCglucagon, 0-240min (optional)(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCglucagon,0-60min (optional)(From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Time to maximum free fatty acids concentration - Tmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Free fatty acids concentration-time curves(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Maximum free fatty acids concentration - Cmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCtriglycerides, 0-60min(From time 0 to 60 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Triglycerides concentration-time curves(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Maximum triglycerides concentration - Cmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Time to maximum triglycerides concentration - Tmax(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Pharmacodynamics - Area under the concentration-time curve - AUCtriglycerides,0-240min(From time 0 to 240 minutes at baseline, 24 hours after a single dose and 24 hours after the forth dose)
  • Anti-ZP7570 antibodies - Incidence and titres(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Safety Lab - Haematological values vs. reference ranges and baseline(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Safety Lab - Clinical chemistry values vs. reference ranges and baseline(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Safety Lab - Urinalysis values vs. reference ranges and baseline(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Safety - Vital signs: blood pressure(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Safety - Vital signs: pulse(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Safety - Physical Examination(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Safety - ECG(From time 0 to 51 days after first dosing (29 days after fourth dosing))
  • Safety - Injection site reactions(From time 0 to 51 days after first dosing (29 days after fourth dosing))

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374Healthy Subjects
NCT02245828Novartis Pharmaceuticals66
Recruiting
Phase 1
A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
NCT06772766Mabwell (Shanghai) Bioscience Co., Ltd.40
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee PainOsteoarthritis
NCT02318407Amgen24
Terminated
Phase 1
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)Atopic Dermatitis
NCT05859724Yellow Jersey Therapeutics AG126
Completed
Phase 1
A Multiple Ascending Dose Study of COR388Alzheimer Disease
NCT03418688Cortexyme Inc.33